Aricept

DRUG14 trials

Sponsors

US Department of Veterans Affairs, National Center for Research Resources (NCRR), Eisai Limited, Eisai Inc., Duke University

Conditions

Alzheimer DiseaseAlzheimer Type DementiaAlzheimer's DiseaseCognitive ImpairmentDementia With Parkinson's DiseaseHealthyHealthy SubjectsMemory Disorders

Phase 1

Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition

CompletedNCT01504516

Dr. Reddy's Laboratories LimitedHealthy

Start: 2009-10-31End: 2009-12-31Updated: 2012-01-06

Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition

CompletedNCT01504503

Dr. Reddy's Laboratories LimitedHealthy

Start: 2009-10-31End: 2009-12-31Updated: 2012-01-06

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

CompletedNCT02968719

Corium, Inc.Alzheimer Disease

Start: 2016-11-30End: 2017-07-11Updated: 2018-08-01

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

CompletedNCT03259958

Corium, Inc.Alzheimer's Disease

Start: 2017-10-30End: 2018-03-14Updated: 2018-08-01

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

CompletedNCT04617782

Corium, Inc.Healthy Subjects

Start: 2020-12-08End: 2021-04-05Updated: 2024-09-19

Phase 2

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

National Center for Research Resources (NCRR)Alzheimer's Disease, Memory Disorders

Updated: 2008-02-05

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

CompletedNCT00103948

Eisai LimitedCognitive Impairment

Start: 2005-02-28End: 2007-02-28Updated: 2015-11-03

Phase 3

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

CompletedNCT00165815

Eisai LimitedDementia With Parkinson's Disease

Start: 2002-08-31End: 2005-07-31Updated: 2013-05-10

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

CompletedNCT01245530

Whanin Pharmaceutical CompanyAlzheimer Type Dementia

Start: 2008-06-30End: 2011-03-31Updated: 2011-06-13

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

Shanghai Mental Health CenterAlzheimer Disease

Start: 2017-08-16End: 2021-02-16Target: 600Updated: 2019-10-22

Phase 4

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

CompletedNCT00018278

US Department of Veterans AffairsAlzheimer Disease

Start: 1998-10-31End: 2001-09-30Updated: 2009-01-21

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

CompletedNCT00230568

Eisai Inc.Alzheimer's Disease

Start: 2005-12-31End: 2007-12-31Updated: 2011-04-01

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

TerminatedNCT00369603

Duke UniversityAlzheimer's Disease

Start: 2006-10-31End: 2007-11-30Updated: 2013-04-11

Unknown Phase

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients

CompletedNCT02158910

Eisai Korea Inc.Alzheimer's Disease

Start: 2015-03-31End: 2016-06-30Updated: 2017-03-07

Related Papers

Bioequivalence and safety comparison of once‐weekly donepezil transdermal system with oral donepezil: results of a phase 1 pharmacokinetic study in healthy volunteers

Alzheimer s & Dementia2022-12-01

Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil

Journal of Alzheimer s Disease2022-09-1616 citations

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

2008-02-28145 citations